The Latest Cardiac and Vascular News
SAN ANTONIO, Oct. 26, 2017 /PRNewswire/ — CeloNova BioSciences, a global medical device company that offers a family of innovative products based upon its proprietary Polyzene™-F nanocoating technology, today announced that the U.S. Federal Drug Administration (FDA) approved expansion of CeloNova’s ongoing clinical trial of its proprietary COBRA PzF™ NanoCoated Coronary […]
A new study has found females and minorities have a greater risk of restenosis and subsequent MACE than “white” men after receiving everolimus-eluting stent implantation. The Study Setup A cohort study that pulled thousands of patients from both the PLATINUM Diversity and PROMUS Element Plus Post-Approval looked at groups of men, women […]
(PresseBox) – BIOTRONIK has announced the start of enrollment of a coronary stent trial aiming at assessing the safety and clinical performance of a new coronary stent in de novo coronary artery lesions. On September 28, first Dr. Marco Moccetti, Cardiocentro Ticino, Lugano, Switzerland, and later on the same day Dr. Lorenz Raeber, University […]
The Federal court upheld a previous coronary stent win over Dr. David Jang Appeals court upholds Boston Scientific win over stent pioneer Jang BY BRAD PERRIELLO, MassDevice A federal appeals court today upheld a Boston Scientific (NYSE:BSX) win over coronary stent pioneer Dr. David Jang. The case dates back to 1999, when Jang won […]
Micell raises $62m for MiStent SES SEPTEMBER 19, 2017 BY BRAD PERRIELLO, Drug Delivery Business News Micell Technologies said last week that it raised a debt-and-equity round worth nearly $62 million from a syndicate of 51 unnamed investors. Paris-based Micell makes the MiStent SES sirolimus-eluting absorbable polymer coronary stent, designed to treat coronary artery […]
CeloNova BioSciences Announces Financing Arrangement with Congruent Investment Partners and SWK Holdings Corporation Proceeds to Support Company Growth, Ongoing Clinical Trial Enrollment and New Product Initiatives CeloNova BioSciences, Inc. (CeloNova), a medical device company that develops, manufactures and markets a family of innovative cardiovascular products based upon its novel Polyzene™-F […]
PRESS RELEASE ABBOTT PARK, Ill., July 25, 2017 — Abbott today announced that the first patient has been enrolled in a clinical study evaluating the short-term use of common blood thinning medicines, called dual antiplatelet therapy (DAPT), after receiving a XIENCE everolimus-eluting coronary stent. The study, called XIENCE Short DAPT, […]
Press Release Singapore, 22 March 2017 – Biosensors International Group, Ltd. (“Biosensors” or the “Company”), a developer, manufacturer and marketer of innovative medical devices, announced today the enrollment of the first American patient in LEADERS FREE II, its new BioFreedom Pivotal Study, conducted under an Investigational Device Exemption (IDE), which […]
